Innovation Unleashed: REPROCELL's Q1 Recap and Insights
13 July 2023
REPROCELL had a productive first quarter of 2023-24, launching new services, winning grants, and publishing research. Find out more in our news release.
Vernal Biosciences Announces Partnership With REPROCELL: Exclusive Distributorship in Japan for mRNA and LNP Formulation Services
11 July 2023
Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to provide mRNA services in Japan at scale for research and clinical applications
Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer
28 June 2023
REPROCELL has entered into a joint research agreement with Keio University regarding the transfer of technology to produce Tumor Infiltrating Lymphocytes (TIL).
Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform
01 June 2023
REPROCELL has collaborated with HNCDI to create a machine learning (ML) platform that simplifies and accelerates the analysis of big data from drug development studies.
REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products
23 May 2023
REPROCELL will now offer CDMO services to manufacture ATMPs generated from mesenchymal stem cells (MSC) through a partnership with Histocell.
End of Q4 update from REPROCELL (2022-23)
04 May 2023
Did you know that REPROCELL is celebrating its 20th anniversary this year? If you missed the commemorative letter from our CEO you can find out more here.
End of Q3 update from REPROCELL (2022-23)
12 December 2022
The final months of 2022 have brought new collaborations, partnerships, and successes to enrich your stem cell and drug discovery research.
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
09 December 2022
The three-month study, conducted at REPROCELL, will assess the binding affinity of the peptide in healthy human and RA synovial tissue.
REPROCELL invests in Histocell, S.L. a Spain-based CDMO
23 November 2022
REPROCELL Inc. decided to invest in Histocell S.L. to strengthen its clinical induced pluripotent stem cell (iPSC) service offerings.
REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPS Service to domestic and overseas customers
13 October 2022
REPROCELL Inc. and JTB Corp. will begin marketing Personal iPS (REPROCELL's iPSC storage and production service) overseas through the JMHC.
REPROCELL Inc. and CIRM sign MOU for special access to clinical iPSCs
05 October 2022
Learn why REPROCELL Inc. has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program.
End of Q2 update from REPROCELL (2022-23)
03 October 2022
Read the end of Q2 update from REPROCELL for the financial year 2022-23. Discover the latest website updates, blog, and news updates.
REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine
31 August 2022
Collaboration at Hartree NCDI combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in AI and machine learning.
Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials
17 August 2022
Learn how scientists at REPROCELL compared the effects of RCD405 with drugs that are currently used to treat respiratory disease in human living bronchi.
Life science after lockdown: SPS returns for 2022
15 August 2022
Discover the first, in-person Saftey Pharmacology Society annual meeting since 2019: a dynamic forum, known for its global networking opportunities.
REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development
08 March 2022
Read how REPROCELL and IBM developed a novel Machine Learning driven precision medicine strategy for drug development.
REPROCELL spotlights the power of smarter biospecimens in new global publication
21 January 2022
REPROCELL has published an article highlighting the power of biospecimens in EBR. Visit the news section of our website to find out more.
Hoth Therapeutics Extends Partnership Agreement with REPROCELL
25 October 2021
Hoth Therapeutics has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in IBD. Find out why.
Bioserve India to sponsor webinar hosted by the Society of Fetal Medicine
15 September 2021
Find out more about Genetic Testing in Fetal Medicine in the upcoming REPROCELL sponsored webinar by the Society of Fetal Medicine.
REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service
02 September 2021
REPROCELL USA has launched a new service to manufacture GMP iPSC-Master Cell Banks (MCB), compliant with the regulatory standards and guidelines.